Skip to content
directory image

AVAHO recognizes the importance of our members' connection to their Industry partners. In order to facilitate ongoing communications between AVAHO members and the industry representatives who may help with treatment options and questions, we are launching an industry directory.

This directory will allow companies to share a primary federal contact, a medical science liaison contact, and website information about your company. Once we have a significant representation of contacts this page will become the directory.

Please participate by clicking the link below and sharing your information.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

AbbVie Inc.

About Us

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas.

1 North Waukegan Road
North Chicago, IL 60064
(800) 255-5162

Primary Contacts

Maureen Harney
Federal Account Executive
(312) 203-5720

Jodi Walker
Director of US Medical Affairs
(607) 542-5034

Products or Services

VENCLEXTA is a BCL-2 inhibitor indicated:

  • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

LUPRON DEPOT (leuprolide acetate for depot suspension):

  • Is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostatic cancer.


About Us

Amgen harnesses the best of biology and technology to make people’s lives easier, fuller, and longer. We draw upon our deep knowledge of science to push beyond what’s known today. With roots in the biotech revolution, we are one of the world’s leading independent biotech companies – fighting the toughest diseases and helping millions of people globally.

1 Amgen Center Drive
Thousand Oaks, CA 91320
(703) 955-6090

Primary Contacts

Keith Knowles
National Account Manager
(703) 955-6090

Dan Flores, PharmD
Medical Value and Access Director
(973) 362-8300

Products or Services

ACTIMMUNE® (interferon gamma 1-b)
AIMOVIG® (erenumab-aooe)
AMJEVITA® (adalimumab-atto)
ARANESP® (darbepoetin alfa)
AVSOLA® (infliximab-axxq)
BLINCYTO® (blinatumomab)
BUPHENYL® (sodium phenylbutyrate)
CORLANOR® (ivabradine)
EPOGEN® (epoetin alfa)
ENBREL® (etanercept)
EVENITY® (romosozumab-aqqg)
IMLYGIC® (talimogene laherparepvec)
KANJINTI® (trastuzumab-anns)
KRYSTEXXA® (pegloticase)
KYPROLIS® (carfilzomib)
LUMAKRAS® (sotorasib)

MVASI® (bevacizumab-awwb)
NEULASTA® (pegfilgrastim)
NEUPOGEN® (filgrastim)
NPLATE® (romiplostim)
OTEZLA® (apremilast)
PARSABIV® (etelcalcetide)
PROCYSBI® (crysteamine bitartrate)
PROLIA® (denosumab)
RAVICTI® (glycerol phenylbutryrate)
REPATHA® (evolocumab)
RIABNI® (rituximab-arrx)
SENSIPAR® (cinacalcet)
TAVNEOS® (avacopan)
TEZSPIRE® (tezepelumab-ekko)
VECTIBIX® (panitumumab)
XGEVA® (denosumab)

Bayer Healthcare


About Us

Science for a better life.

1 Bayer Blvd
Whippany, NJ 07981
(862) 404-3000

Primary Contacts

Eric Patterson
National Account Director, VA
(608) 301-7405

Dr. Jay Jhaveri
Medical Director, US Oncology
(516) 721-7568

Products or Services

Nubeqa (darolutamide)
Xofigo (Radium 223)
Stivarga (regorafenib)
Nexavar (sorafenib)
Vitrakvi (larotrectinib)



About Us

Build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.

2955 Campus Drive, 2nd Floor
San Mateo, CA 94403
(615) 414-6211

Primary Contacts

Eric Kite
National Account Director
(615) 414-6211

Lee Ding
Sr. HEOR Field Director
(628) 222-5293

Products or Services

BRUKINSA is a prescription medicine used to treat adults with:

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Waldenström's macroglobulinemia (WM).
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
  • Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.

Blueprint Medicines


About Us

Blueprint Medicines aims to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible.

45 Sidney St
Cambridge, MA 02139
(617) 374-7580

Primary Contacts

Dean Petree
National Account Executive
(612) 669-9731

Rahul Kalathiya
Senior Medical Science Liaison
(859) 312-9053

Products or Services

AYVAKIT® (avapritinib) is a prescription medicine used to treat adults with:

  • A certain type of stomach, bowel, or esophagus cancer called gastrointestinal stromal tumor (GIST) that cannot be treated with surgery or that has spread to other parts of the body (metastatic), and that is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes. Your healthcare provider will perform a test to make sure that you have this abnormal PDGFRA gene and that AYVAKIT is right for you.


  • Advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). AYVAKIT is not recommended for the treatment of AdvSM in people with low platelet counts (less than 50 x 109/L).
  • Indolent systemic mastocytosis (ISM). AYVAKIT is not recommended in people with low platelet counts (less than 50 X 109/L).

Deciphera Pharmaceuticals


About Us

One Mission, Inspired by Patients: Defeat Cancer.

200 Smith Street
Waltham, MA 02451
(781) 209-6400

Primary Contacts

Ben Stutzman
Associate Director Market Access
(361) 549-8937

Nicholas Zeringo
Associate Scientific Director, Medical Affairs
(856) 912-1181

Products or Services

QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

DSS, Inc.


About Us

12575 Us Hwy 1
Suite 200
Juno Beach, FL 33408
(561) 284-7000

Primary Contacts

Rob Gill
Strategic Federal Account Manager
(561) 629-3605

Eisai Inc.


About Us

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides.

200 Metro Blvd
Nutley, AK 07110
(214) 586-6800

Primary Contacts

Jeff Granberry
Director Federal Markets
(214) 505-5584

Dr. Christine Divers, PhD
Director, US Field Health Econ & Outcome Research and Real World Evidence Eisai Inc
(551) 502-1029

Eli Lilly & Company


About Us

Lilly unites caring with discovery to create medicines that make life better for people around the world.

Lilly Corporate Center
893 Delaware St
Indianapolis, IN 46225
(317) 292-2975

Primary Contacts

Aeron P. Burns
Regional Oncology Account Manager
(317) 292-2975

Amine Ale-Ali
National Oncology Outcomes Liaison
(619) 496-6498

Products or Services

Patient educational materials for all promoted products.



About Us

We are shaping the future of oncology for patients.

1851 Harbor Bay Parkway
Alameda, CA 94502
(503) 804-5087

Primary Contacts

Joan Gratton
Senior Director National Accounts - Federal
(503) 804-5087

Tasha Hall
Medical Director
(412) 680-5256

Products or Services

cabozantinib has 3 indications in:
* Advanced RCC: In combination with nivolumab to treat renal cell carcinoma (RCC) that has spread (advanced RCC), and you have not already had treatment for your advanced RCC
Alone to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC)

* 2nd line HCC

* DTC:Adults and children 12 years of age and older who have a type of thyroid cancer called differentiated thyroid cancer (DTC) that has spread (locally advanced or metastatic), and,
has progressed after treatment with a VEGFR-targeted treatment, and
your DTC can no longer be treated with radioactive iodine, or you are not able to receive radioactive iodine treatment.

Foundation Medicine


About Us

400 Summer Street
Boston, MA 02210
(888) 988-3639

Primary Contacts

Andy Fedor
Federal Account Director
(614) 226-3082

Gilead Sciences


About Us

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

333 Lakeside Drive
Foster City, CA 94404
(650) 574-3000

Primary Contacts

David Baran
Senior Director, National Federal Accounts, Market Access
(630) 209-0588

Chase Williams, PharmD., MBA
Principal Medical Scientist
(708) 288-5140

Incyte Corporation


About Us

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

1801 Augustine Cut-Off
Wilmington, DE 19803
(855) 446-2983

Primary Contacts

Brian Gaughran
Field Associate Director, Government and Strategic Accounts
(516) 246-4129

Anthony Duca
Senior Director, Government Accounts
(609) 694-5427

Products or Services

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.

Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. We are creating a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists.

J&J Innovative Medicine


About Us

2538 Henry Street
Augusta, GA 30904
(706) 469-0904

Primary Contacts

Karen Watkins
Federal Account Director
(585) 478-8968

Brian Macomson
Scientific Director
(706) 469-0904

Kite Pharma


About Us

At Kite, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit.

We believe cell therapy has the ability to change the way cancer is treated. Our industry-leading cell therapy technology uses the power of a patient's own immune system (their white blood cells) to target and attack their cancer cells.

2400 Broadway
Santa Monica, CA 90404
(310) 824-9999

Primary Contacts

Lisa Zuccarello, MHA
Director, US Health Systems
(732) 547-3868

Ima Garcia
Director East, MSL Team
(312) 890-6774



About Us

1531 Evanvale Dr
Allen, TX 75013
(214) 543-4078

Primary Contacts

Jeremy Huff
Director of Government Programs
(214) 543-4078

Menarini Stemline


About Us

To build a leading biopharmaceutical company focused on improving the lives of cancer patients by developing and marketing innovative oncology therapeutics that target difficult-to-treat cancers.

750 Lexington Avenue, 11th Floor
New York, NY 10022
(410) 271-2322

Primary Contacts

William Gardner
Senior Director National Payer Accounts
(410) 271-2322

Eric Kruep
Executive Director, Clinical & Value Evidence Liaison
(813) 732-9592

Products or Services

Stemline is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by cancer.

Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.

The information in the table reflects Stemline’s development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products have not been established and marketing approval has yet to be granted by regulatory authorities.



About Us

We are a targeted oncology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. Unified for patients, our vision is to unlock the science behind the promise of a life beyond cancer.

3545 Cray Ct
San Diego, CA 92121
(844) 647-2841

Primary Contacts

Trebla Grant
National Access Director
(281) 210-4303

Anna Vasyman
Regional Health Outcomes Director
(847) 293-9776

Products or Services

The Mirati & Me Patient Support Program offers comprehensive support services for eligible patients, caregivers, and healthcare professionals, including personalized education and financial resources to help patients who have been prescribed Mirati medications start and stay on treatment as directed by their physician.

Pharmacyclics LLC, an AbbVie Company


About Us

Pharmacyclics is an AbbVie company based in the Bay Area, California. Our charge is to help people impacted by cancer and immune-mediated diseases by focusing on the development of safe and effective treatment options. We will know that our mission has been achieved when patients and their families have rediscovered the Magic of Normal – where disease no longer defines the every day.

1000 Gateway Blvd
South San Francisco, CA 94080
(408) 215-3000

Primary Contacts

James Byrd
Federal Account Executive
(443) 926-6016

Jill Drury
National Medical Outcomes and Science Liaison
(847) 935-8089



About Us

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We’re driven by a singular mission—to make a difference for people impacted by cancer.

21717 30th Drive SE
Bothell, WA 98021
(571) 375-6471

Primary Contacts

Marc Miller
Associate Director - US Market Access
(571) 375-6471

Rachel Atkinson
Clinical Value & Outcomes Liaison
(425) 308-0057

Products or Services

As an industry leader in antibody–drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology.

We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.

Scroll To Top